Project Grant R15CA309667
Award Date 5/1/26
Completion Date 4/30/29
Dollars Obligated $428K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Woodfin, NC 28804, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of North Carolina at Chapel Hill a Project Grant totaling $624,194 under the Cancer Biology Research program (CFDA 93.396) effective April 1, 2026 through March 31, 2031. This five-year award supports fundamental research investigating how the integrated stress response (ISR) regulates CD8+ tumor-infiltrating lymphocyte (TIL) function and immunometabolism within the tumor microenvironment (TME). The research...
- Federal Project Grant Award Summary The National Cancer Institute awarded University of North Carolina at Charlotte $150,784 under the Cancer Biology Research program (CFDA 93.396) beginning September 1, 2025 and concluding August 31, 2027. This project grant funds fundamental research investigating the interplay between the HSP70 (Heat Shock Protein 70) molecular chaperone and cyclin D1/CLN3 proteins, with implications for understanding cell cycle regulation and potential anticancer therapeutic...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of North Carolina at Chapel Hill a Project Grant of $627,676 under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025 through August 31, 2028. This three-year research initiative focuses on developing and validating genetically-encoded biosensors to characterize intercellular heterogeneity in cell cycle quiescence—specifically the spectrum of quiescent (dormant) states in cancer...
- Federal Project Grant Award Summary The University of North Carolina at Chapel Hill received a $2,554,662 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective March 5, 2026, through February 28, 2031. This comprehensive research initiative focuses on developing biomaterial-enhanced Chimeric Antigen Receptor (CAR) T-cell and Natural Killer T (NKT) cell therapies to improve treatment outcomes for glioblastoma, a highly...
- Federal Grant Award Summary The National Cancer Institute (NCI), under its Cancer Biology Research program (CFDA 93.396), awarded a $661,721 Project Grant to the University of California, San Diego, with an award date of April 1, 2026, and a completion date of March 31, 2031. This five-year research initiative focuses on systematic functional mapping and interrogation of oncogenic intrinsically disordered regions (IDRs) in cancer driver proteins. The project will utilize novel high-throughput...
- Federal Grant Award Summary The University of North Carolina at Chapel Hill received a $207,802 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) for the period May 1, 2026 through April 30, 2029. The award supports the development of multiplexed multiscale imaging technologies and automated analysis systems designed to advance cellular immunotherapy research. Specifically, the project will develop novel fluorescent...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of North Carolina at Chapel Hill $384,630 under the Cancer Biology Research program (CFDA 93.396) on April 10, 2026, for a project titled "Identifying Immune-Mediated Mechanisms of RAS Inhibitor Efficacy and Resistance in Pancreatic Cancer." The award, with a completion date of March 31, 2027, funds research designed to elucidate how tumor-immune microenvironment remodeling contributes to the...
- Federal Grant Award Summary The University of California, Santa Barbara received a $402,400 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) effective September 1, 2025, through August 31, 2027. This award supports fundamental research investigating the structure-function relationship of the Wnt destruction complex (DC), a protein machine comprising disordered scaffold proteins APC and AXIN that regulate critical signaling interactions in...
- Federal Grant Award Summary The National Cancer Institute awarded $544,712 to the University of North Carolina at Charlotte through the Cancer Cause and Prevention Research program (CFDA 93.393) on July 15, 2025, for a project titled "Defining Novel Roles of the DNA Repair Factor REV7 in P53 Signaling and Regulation." The three-year project, concluding June 30, 2028, will investigate the mechanistic relationship between the DNA repair protein REV7 and the tumor suppressor protein...
- Federal Project Grant Award Summary The National Cancer Institute awarded $399,829 to the University of North Carolina at Chapel Hill under the Cancer Biology Research program (CFDA 93.396) for a two-year project (September 1, 2025–August 31, 2027) investigating the role of Fusobacterium nucleatum in breast cancer progression and therapeutic resistance. The research will characterize how this bacterium, detected in approximately 30% of breast cancer cases, alters the tumor microenvironment and...